Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-029
- Development stage
- Preclinical
- Lead developer
- Pangea Pharmaceuticals
- Modality
- Small Molecules
01
Overview
P-029 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of urinary tract infections (UTIs). Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated and generic products rather than novel molecular entities. As a pipeline candidate, specific technical details regarding the active pharmaceutical ingredient, molecular target, and modality of P-029 have not been publicly disclosed. However, given the company's focus, P-029 is likely a new formulation or a generic version of an existing antimicrobial agent intended to improve therapeutic outcomes or patient compliance in the management of UTIs.
Beyond the preview
Go deeper on P-029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-029.